Edwards Lifesciences (EW) has been gaining from strength across all key segments. Innovation also aids growth. The stock carries a Zacks Rank #2 (Buy) currently.Edwards’ Surgical Structural Heart business pioneered the innovative RESILIA tissue, which is backed by more than 40 years of the company’s tissue technology leadership. The RESILIA portfolio has been widely adopted because of the excellent durability of its proven tissue technology. The company is optimistic about the future of this technology as i ...